SBT8230 

SBT8230 is an ASGR1-targeted TLR8 agonist and an ASGR1-TLR8 immune TAC conjugate. SBT8230 achieves liver enrichment via conjugation with an anti-ASGR1 antibody, activates myeloid cells and induces anti-HBV immune responses. SBT8230 is applicable to research on chronic hepatitis B infection. Isotype comparison: HY-P99001^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

SBT8230 acts as a liver-localized TLR8 agonist targeting ASGR1, activates myeloid cells, and induces anti-HBV immune responses and antiviral T cell responses in hepatic cellular models^[1][2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SBT8230 induces anti-HBs seroconversion and antiviral T cell responses in HBV mouse models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

432  [NCBI]

P07306

ASGR1

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gan L, et al. A High-Throughput Cell-Based Luciferase Reporter Assay for Identifying Inhibitors of ASGR1. Int J Mol Sci. 2025;26(10):4590. Published 2025 May 10.  [Content Brief]

  [2]. Mak LY, et al. New strategies for the treatment of chronic hepatitis B. Trends Mol Med. 2022;28(9):742-757.